Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today the merger of two Taiwan subsidiaries, involving a manufacturing and marketing subsidiary, Eisai Taiwan Inc. (Headquarters: Taipei, Chairman and President and CEO: Yoichi Endo), and another marketing subsidiary in Taiwan, Wei-zai Co., Ltd. (Headquarters: Taipei, President: Fang-ming Chang). The surviving company is Eisai Taiwan Inc.
Eisai set up its first sales office in Taipei in 1967 and has since developed and expanded business in Taiwan, marked by the establishment of a manufacturing facility and marketing subsidiaries. Eisai's current core business in Taiwan is manufacturing and marketing of pharmaceuticals including major global products,
ARICEPT
, an Alzheimer's disease treatment and
PARIET, a proton pump inhibitor.
Through this merger, the surviving company, Eisai Taiwan Inc. will aim at expanding marketing efforts and enhancing competitiveness in the market to improve performance in the Taiwan pharmaceutical business and provide further contributions to the benefits of patients.
[Surviving Company Outline]
| Company Name: | Eisai Taiwan Inc. |
| Location: | Taipei, Taiwan |
| Representative: | Chairman and CEO, Yoichi Endo |
| Capital: | 270 million NT dollar (approximately 920 million yen) |
| Net Sales: | Approximately 1.5 billion yen (estimate for fiscal 2005) |
| Number of employees: | Approximately 100
(including 30 medical representatives) |
| Operations: | Manufacture, import/export, sale of pharmaceuticals and manufacture, import, sale of quasi drugs |
| Form: | Limited liability company |
